Market Cap 149.96B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.73
Forward PE 8.94
Profit Margin 12.42%
Debt to Equity Ratio 0.74
Volume 23,126,904
Avg Vol 44,402,004
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 84%
Beta 0.34
Analysts Sell
Price Target $28.60

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Micheal_Pothead
Micheal_Pothead Aug. 14 at 9:04 PM
$PFE just a PSA, we crossed the 200 week moving average last week and held it this week
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 7:45 PM
$PFE shorts are mad
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 7:14 PM
$PFE 27.01 close would confirm 30 imo
2 · Reply
BarkingPuppy
BarkingPuppy Aug. 14 at 7:05 PM
$ELTP $DJT $GME $PFE $JNJ The Rumors in the Bio-tech world are going crazy. Who is going to Grab ELTP in America Before a Foreign Company Buys them???? I would like to keep it in American Hands, I think their ART technology is far to great and powerful to let a none US company acquire this There is no official corporate announcement or confirmed agreement that Elite Pharmaceuticals (ELTP) is being bought by a foreign buyer. Online retail investor communitie have heavily speculated about a potential company buyout—including theories involving international or foreign acquirers motivated by manufacturing capacities or tariff strategies. However, these claims remain unverified market speculation and rumor rather than official business operations. The company's management has previously discussed a sale or buyout as a strategic option to maximize shareholder value or address listing requirements, but no foreign acquisition deal has been finalized or announced.
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 14 at 6:34 PM
$IGC Pay attention—you're about to see a late-session surge right before the closing bell. Supporting Factors for Late-Day Moves Institutional MOC Orders: Market-On-Close (MOC) imbalance data is released in the final 20–30 minutes, frequently driving sharp institutional volume and rapid price jumps into the bell. Intraday Short Covering: Day traders and short sellers closing out intraday positions before the bell forces quick buy-side pressure to prevent overnight gap risk. Options Gamma Hedging: Market makers rebalancing delta-neutral positions toward the end of the session can accelerate momentum in the underlying asset if key strike prices are broken. Power Hour Volume: Trading volume routinely spikes during the final hour as funds align capital allocations before liquidity dries up post-market. $UMAC $PFE $MRNA
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 14 at 5:46 PM
$PFE i love a good undercut and rally
0 · Reply
EmbraceVolatility
EmbraceVolatility Aug. 14 at 5:29 PM
$PFE 1 more dollar until 52 week high (divvy adjusted). Then we see if we can breakout. $30 anyone?
1 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 5:20 PM
$PMN Guggenheim raised PT to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $PFE $JNJ $BMY
0 · Reply
CapitalMonk
CapitalMonk Aug. 14 at 4:56 PM
$PFE Price: $26.76 (-0.13%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.09% RSI: 74.2 | Momentum: Moderate Volume: -72.3% vs avg Volatility: 1.18% Support: $24.23 | Resistance: $27.20 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
BarkingPuppy
BarkingPuppy Aug. 14 at 4:24 PM
$ELTP $PFE $GME $META GREAT Call today. They Mentioned Trump ( in a good way ) One of the most talked-about rumors circulating is a potential share buyback program. If this comes to fruition, it would be a powerful signal of confidence from the company’s leadership, aiming to increase shareholder value by reducing outstanding shares and demonstrating belief in the company’s future prospects. Interestingly, for the first time ever, there was no mention of SequestOx during the call. Historically, SequestOx has been a frequent topic, so its absence is notable. In the world of corporate communications, silence on a previously prominent subject often suggests positive developments—nine times out of ten, it means there’s good news brewing behind the scenes. ELTP stock is now in play after this call. ( Roaring Kitty ? )
2 · Reply
Latest News on PFE
Pfizer (PFE) CEO Buys $1 Million of Company Stock

2026-08-14T18:45:04.000Z - 2 hours ago

Pfizer (PFE) CEO Buys $1 Million of Company Stock


Pfizer price target lowered to $31 from $35 at Guggenheim

2026-08-07T11:40:49.000Z - 7 days ago

Pfizer price target lowered to $31 from $35 at Guggenheim


Pfizer’s (PFE) Q2 Earnings Support a Bullish View

2026-08-06T13:09:00.000Z - 8 days ago

Pfizer’s (PFE) Q2 Earnings Support a Bullish View


Pfizer price target raised to $27 from $26 at BofA

2026-08-05T10:45:23.000Z - 9 days ago

Pfizer price target raised to $27 from $26 at BofA


Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Earnings Call Transcript: Q2 2026


Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Earnings release: Q2 2026


Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Slides: Q2 2026


Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Quarterly report: Q2 2026


Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:24 AM EDT - 10 days ago

Pfizer Post Loss on Higher Revenue


Pfizer reports Q2 adjusted EPS 77c, consensus 68c

2026-08-04T10:52:17.000Z - 10 days ago

Pfizer reports Q2 adjusted EPS 77c, consensus 68c


Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 5 weeks ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low


Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 7 weeks ago

Pfizer Declares Third-Quarter 2026 Dividend


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 7 weeks ago

Pfizer dismissed from US states' drug price-fixing lawsuit


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 2 months ago

Pfizer CFO Dave Denton to step down, leave company in August


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Chief Financial Officer Transition


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update


Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 2 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026


Micheal_Pothead
Micheal_Pothead Aug. 14 at 9:04 PM
$PFE just a PSA, we crossed the 200 week moving average last week and held it this week
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 7:45 PM
$PFE shorts are mad
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 7:14 PM
$PFE 27.01 close would confirm 30 imo
2 · Reply
BarkingPuppy
BarkingPuppy Aug. 14 at 7:05 PM
$ELTP $DJT $GME $PFE $JNJ The Rumors in the Bio-tech world are going crazy. Who is going to Grab ELTP in America Before a Foreign Company Buys them???? I would like to keep it in American Hands, I think their ART technology is far to great and powerful to let a none US company acquire this There is no official corporate announcement or confirmed agreement that Elite Pharmaceuticals (ELTP) is being bought by a foreign buyer. Online retail investor communitie have heavily speculated about a potential company buyout—including theories involving international or foreign acquirers motivated by manufacturing capacities or tariff strategies. However, these claims remain unverified market speculation and rumor rather than official business operations. The company's management has previously discussed a sale or buyout as a strategic option to maximize shareholder value or address listing requirements, but no foreign acquisition deal has been finalized or announced.
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 14 at 6:34 PM
$IGC Pay attention—you're about to see a late-session surge right before the closing bell. Supporting Factors for Late-Day Moves Institutional MOC Orders: Market-On-Close (MOC) imbalance data is released in the final 20–30 minutes, frequently driving sharp institutional volume and rapid price jumps into the bell. Intraday Short Covering: Day traders and short sellers closing out intraday positions before the bell forces quick buy-side pressure to prevent overnight gap risk. Options Gamma Hedging: Market makers rebalancing delta-neutral positions toward the end of the session can accelerate momentum in the underlying asset if key strike prices are broken. Power Hour Volume: Trading volume routinely spikes during the final hour as funds align capital allocations before liquidity dries up post-market. $UMAC $PFE $MRNA
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 14 at 5:46 PM
$PFE i love a good undercut and rally
0 · Reply
EmbraceVolatility
EmbraceVolatility Aug. 14 at 5:29 PM
$PFE 1 more dollar until 52 week high (divvy adjusted). Then we see if we can breakout. $30 anyone?
1 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 5:20 PM
$PMN Guggenheim raised PT to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $PFE $JNJ $BMY
0 · Reply
CapitalMonk
CapitalMonk Aug. 14 at 4:56 PM
$PFE Price: $26.76 (-0.13%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.09% RSI: 74.2 | Momentum: Moderate Volume: -72.3% vs avg Volatility: 1.18% Support: $24.23 | Resistance: $27.20 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
BarkingPuppy
BarkingPuppy Aug. 14 at 4:24 PM
$ELTP $PFE $GME $META GREAT Call today. They Mentioned Trump ( in a good way ) One of the most talked-about rumors circulating is a potential share buyback program. If this comes to fruition, it would be a powerful signal of confidence from the company’s leadership, aiming to increase shareholder value by reducing outstanding shares and demonstrating belief in the company’s future prospects. Interestingly, for the first time ever, there was no mention of SequestOx during the call. Historically, SequestOx has been a frequent topic, so its absence is notable. In the world of corporate communications, silence on a previously prominent subject often suggests positive developments—nine times out of ten, it means there’s good news brewing behind the scenes. ELTP stock is now in play after this call. ( Roaring Kitty ? )
2 · Reply
nimii
nimii Aug. 14 at 4:16 PM
$PFE ☹️
0 · Reply
TraderDaKing
TraderDaKing Aug. 14 at 4:09 PM
$ELTP $PFE $BAC $SPCX Call Conference was Great. Up-listing and Partnership confirmed and in the works. Thank God. Watch the Big Share buyback now through next year. Should drive it to 1.20 range.
1 · Reply
StocktwitsNews
StocktwitsNews Aug. 14 at 3:54 PM
Why Did VALN Stock Surge 24% Today? $VALN $PFE https://stocktwits.com/news/equity/markets/why-did-valn-stock-surge-24-today/cZotV7rRJ0j
0 · Reply
TraderDaKing
TraderDaKing Aug. 14 at 3:28 PM
$JNJ $PFE $LLY $MRNA I know you are listening and buying after the new during the call. Elite Pharma. Welcome to the Big Times.
0 · Reply
Samishere
Samishere Aug. 14 at 3:27 PM
1 · Reply
TraderDaKing
TraderDaKing Aug. 14 at 3:23 PM
$ELTP $GME $DJT $PFE YOU DO NOT WANT TO MISS THIS CONFERENCE CALL. ELTP STOCK WILL RUN AFTER THIS CALL. Date: August 14, 2026 Time: 11:30 AM EDT Dial-in numbers: 1-800-346-7359 (domestic) 1-973-528-0008 (international) Conference number: 98840
1 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 3:16 PM
$PFE bought my 27s back just in case
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 14 at 2:57 PM
$KPTI $PFE $CCCC $BMY ⚾️ 🥧 🇺🇸 💪 🏦 🤷‍♂️ 💊 🏃‍♂️ Keep slugging America. We got this. 🏆
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 14 at 2:19 PM
$IGC is entering a historic inflection point—with its first true Phase 2 binary catalyst, advancing regulatory infrastructure, and growing clinical-data capabilities, a successful CALMA readout could dramatically re-rate the company and unlock a whole new valuation tier. 🚀📈 $PFE $ABBV
0 · Reply
chop14
chop14 Aug. 14 at 2:15 PM
$ARTL still nice but still low volume ! $JNJ $PFE $SLDB $LLY
0 · Reply
pineconecameo
pineconecameo Aug. 14 at 2:07 PM
$PFE back to $27 and $NVDA $230 ♻️
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 1:55 PM
$PFE another reminder that max pain today is 26.50 🫩
1 · Reply